Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

NCT05928806 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

120

Enrollment

OTHER

Sponsor class

Stopped Interim Analysis

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: Botensilimab
DRUG: Balstilimab
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Michael B. Atkins, MD

Collaborators

[object Object]
[object Object]